139 related articles for article (PubMed ID: 31378570)
1. An investigation of targeted inhibition of transcription factor activity with pyrrole imidazole polyamide (PA) in chronic myeloid leukemia (CML) blast crisis cells.
Hayatigolkhatmi K; Padroni G; Su W; Fang L; Gómez-Castañeda E; Hsieh YC; Jackson L; Pellicano F; Burley GA; Jørgensen HG
Bioorg Med Chem Lett; 2019 Sep; 29(18):2622-2625. PubMed ID: 31378570
[TBL] [Abstract][Full Text] [Related]
2. Investigation of a minor groove-binding polyamide targeted to E2F1 transcription factor in chronic myeloid leukaemia (CML) cells.
Hayatigolkhatmi K; Padroni G; Su W; Fang L; Gómez-Castañeda E; Hsieh YC; Jackson L; Holyoake TL; Pellicano F; Burley GA; Jørgensen HG
Blood Cells Mol Dis; 2018 Mar; 69():119-122. PubMed ID: 29217295
[No Abstract] [Full Text] [Related]
3. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
Carter BZ; Mak PY; Mak DH; Ruvolo VR; Schober W; McQueen T; Cortes J; Kantarjian HM; Champlin RE; Konopleva M; Andreeff M
Oncotarget; 2015 Oct; 6(31):30487-99. PubMed ID: 26431162
[TBL] [Abstract][Full Text] [Related]
5. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
[TBL] [Abstract][Full Text] [Related]
6. Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.
Yang H; Chennamaneni LR; Ho MWT; Ang SH; Tan ESW; Jeyaraj DA; Yeap YS; Liu B; Ong EH; Joy JK; Wee JLK; Kwek P; Retna P; Dinie N; Nguyen TTH; Tai SJ; Manoharan V; Pendharkar V; Low CB; Chew YS; Vuddagiri S; Sangthongpitag K; Choong ML; Lee MA; Kannan S; Verma CS; Poulsen A; Lim S; Chuah C; Ong TS; Hill J; Matter A; Nacro K
J Med Chem; 2018 May; 61(10):4348-4369. PubMed ID: 29683667
[TBL] [Abstract][Full Text] [Related]
7. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
[TBL] [Abstract][Full Text] [Related]
8. BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph
Peter B; Eisenwort G; Sadovnik I; Bauer K; Willmann M; Rülicke T; Berger D; Stefanzl G; Greiner G; Hoermann G; Keller A; Wolf D; Čulen M; Winter GE; Hoffmann T; Schiefer AI; Sperr WR; Zuber J; Mayer J; Valent P
Am J Hematol; 2022 Sep; 97(9):1215-1225. PubMed ID: 35794848
[TBL] [Abstract][Full Text] [Related]
9. Morphine activates blast-phase chronic myeloid leukemia cells and alleviates the effects of tyrosine kinase inhibitors.
Zhou Z; Liu T; Zhang J
Biochem Biophys Res Commun; 2019 Dec; 520(3):560-565. PubMed ID: 31615652
[TBL] [Abstract][Full Text] [Related]
10. The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia.
Huang W; Luan CH; Hjort EE; Bei L; Mishra R; Sakamoto KM; Platanias LC; Eklund EA
Leukemia; 2016 Jul; 30(7):1502-9. PubMed ID: 26984787
[TBL] [Abstract][Full Text] [Related]
11. New routes to eradicating chronic myelogenous leukemia stem cells by targeting metabolism.
Naka K
Int J Hematol; 2021 May; 113(5):648-655. PubMed ID: 33666817
[TBL] [Abstract][Full Text] [Related]
12. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
13. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.
Carter BZ; Mak PY; Mu H; Zhou H; Mak DH; Schober W; Leverson JD; Zhang B; Bhatia R; Huang X; Cortes J; Kantarjian H; Konopleva M; Andreeff M
Sci Transl Med; 2016 Sep; 8(355):355ra117. PubMed ID: 27605552
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of alkylating pyrrole-imidazole polyamide conjugates by a novel method for high-throughput sequencer.
Kashiwazaki G; Maeda R; Kawase T; Hashiya K; Bando T; Sugiyama H
Bioorg Med Chem; 2018 Jan; 26(1):1-7. PubMed ID: 29224995
[TBL] [Abstract][Full Text] [Related]
15. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
[TBL] [Abstract][Full Text] [Related]
16. Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia.
Borges CS; Ferreira AF; Almeida VH; Gomes FG; Berzoti-Coelho MG; Cacemiro MDC; Nunes NS; Figueiredo-Pontes LL; Simões BP; Castro FA; Monteiro RQ
Exp Hematol; 2018 Oct; 66():50-62. PubMed ID: 30076949
[TBL] [Abstract][Full Text] [Related]
17. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.
Lim S; Saw TY; Zhang M; Janes MR; Nacro K; Hill J; Lim AQ; Chang CT; Fruman DA; Rizzieri DA; Tan SY; Fan H; Chuah CT; Ong ST
Proc Natl Acad Sci U S A; 2013 Jun; 110(25):E2298-307. PubMed ID: 23737503
[TBL] [Abstract][Full Text] [Related]
18. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
19. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.
Copland M; Pellicano F; Richmond L; Allan EK; Hamilton A; Lee FY; Weinmann R; Holyoake TL
Blood; 2008 Mar; 111(5):2843-53. PubMed ID: 18156496
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]